

HLAVNÍ TÉMA

HODNOCENÍ ÚČINNOSTI LÉČBY ROZTROUŠENÉ SKLERÓZY V PRAXI, VÝVOJ KONCEPTU NEDA

25;15:17562864211066751. doi: 10.1177/17562864211066751. PMID: 35096143; PMCID: PMC8793117.

4. Giovannoni G, Tomic D, Bright JR, Havrdová E. "No evident disease activity": The use of combined assessments in the management of patients with multiple sclerosis. *Mult Scler*. 2017 Aug;23(9):1179-1187. doi: 10.1177/1352458517703193. Epub 2017 Apr 6. PMID: 28381105; PMCID: PMC5536258.

5. Havrdová E, a kol. Roztroušená skleróza, MF 2013, ISBN 978-80-204-3154-7.

6. Havrdová E, Arnold DL, Bar-Or A, et al. No evidence of disease activity (NEDA) analysis by epochs in patients with relapsing multiple sclerosis treated with ocrelizumab vs interferon beta-1a. *Mult Scler J Exp Transl Clin*. 2018 Mar 12;4(1):2055217318760642. doi: 10.1177/2055217318760642. PMID: 29568544; PMCID: PMC5858626.

7. Havrdova E, Galetta S, Hutchinson M, et al. Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. *Lancet Neurol*. 2009 Mar;8(3):254-60. doi: 10.1016/S1474-4422(09)70021-3. Epub 2009 Feb 7. PMID: 19201654.

8. Havrdova E, Giovannoni G, Stefoski D, et al. Disease-activity-free status in patients with relapsing-remitting multiple sclerosis treated with daclizumab high-yield process in the SELECT study. *Mult Scler*. 2014 Apr;20(4):464-70. doi: 10.1177/1352458513502113. Epub 2013 Sep 10. PMID: 24022270.

9. Kappos L, De Stefano N, Freedman MS, et al. Inclusion of brain volume loss in a revised measure of 'no evidence of disease activity' (NEDA-4) in relapsing-remitting multiple sclerosis. *Mult Scler*. 2016 Sep;22(10):1297-305. doi: 10.1177/1352458515616701. Epub 2015 Nov 19. PMID: 26585439; PMCID: PMC5015759.

10. Kappos L, Wolinsky JS, Giovannoni G, et al. Contribution of Relapse-Independent Progression vs Relapse-Associated Worsening to Overall Confirmed Disability Accumulation in Typical Relapsing Multiple Sclerosis in a Pooled Analysis of 2 Randomized Clinical Trials. *JAMA Neurol*. 2020 Sep 1;77(9):1132-1140. doi: 10.1001/jamaneurol.2020.1568. PMID: 32511687; PMCID: PMC7281382.

11. Lebrun-Frénay C, Siva A, Sormani MP, et al. TERIS Study Group. Teriflunomide and Time to Clinical Multiple Sclerosis in Patients With Radiologically Isolated Syndrome: The TERIS Randomized Clinical Trial. *JAMA Neurol*. 2023 Oct 1;80(10):1080-1088. doi: 10.1001/jamaneurol.2023.2815. PMID: 37603328; PMCID: PMC10442780.

12. Okuda DT, Kantarci O, Lebrun-Frénay C, et al. Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome. *Ann Neurol*. 2023 Mar;93(3):604-614. doi: 10.1002/ana.26555. Epub 2022 Dec 10. PMID: 36401339.

13. Phillips JT, Giovannoni G, Lublin FD, et al. Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with

relapsing multiple sclerosis. *Mult Scler*. 2011 Aug;17(8):970-9. doi: 10.1177/1352458511399611. Epub 2011 Mar 18. PMID: 21421809.

14. Polman CH, O'Connor PW, Havrdova E, et al.; AFFIRM Investigators. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. *N Engl J Med*. 2006 Mar 2;354(9):899-910. doi: 10.1056/NEJMoa044397. PMID: 16510744.

15. Rotstein DL, Healy BC, Malik MT, et al. Evaluation of no evidence of disease activity in a 7-year longitudinal multiple sclerosis cohort. *JAMA Neurol*. 2015 Feb;72(2):152-8. doi: 10.1001/jamaneurol.2014.3537.

16. Uher T, Havrdova EK, Benkert P, et al. Measurement of neurofilaments improves stratification of future disease activity in early multiple sclerosis. *Mult Scler*. 2021 Nov;27(13):2001-2013. doi: 10.1177/13524585211047977. Epub 2021 Oct 6. PMID: 34612753.

17. Uher T, Havrdova E, Sobisek L, et al. Is no evidence of disease activity an achievable goal in MS patients on intramuscular interferon beta-1a treatment over long-term follow-up? *Mult Scler*. 2017 Feb;23(2):242-252. doi: 10.1177/1352458516650525. Epub 2016 Jul 11. PMID: 27230790.

18. University of California, San Francisco MS-EPIC Team, Cree BAC, Hollenbach JA, Bove R, et al. Silent progression in disease activity-free relapsing multiple sclerosis. *Ann Neurol*. 2019 May;85(5):653-666. doi: 10.1002/ana.25463. Epub 2019 Mar 30. PMID: 30851128; PMCID: PMC6518998.

6. NEURO-MUSKULÁRNÍ FÓRUM

NEUROMUSKULÁRNÍ SEKCE ČNS



2.–3. 10. 2025

Hotel Kraskov

Třemošnice-Starý Dvůr



www.neuforum.cz